Literature DB >> 17210832

Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy.

Veerle A M van de Schans1, Susanne W M van den Borne, Agnieszka E Strzelecka, Ben J A Janssen, Jos L J van der Velden, Ramon C J Langen, Antony Wynshaw-Boris, Jos F M Smits, W Matthijs Blankesteijn.   

Abstract

The hypertrophic response of the heart has been recognized recently as the net result of activation of prohypertrophic and antihypertrophic pathways. Here we report the involvement of the Wnt/Frizzled pathway in the onset of cardiac hypertrophy development. Stimulation of the Wnt/Frizzled pathway activates the disheveled (Dvl) protein. Disheveled subsequently can inhibit glycogen synthase kinase-3beta, a protein with potent antihypertrophic actions through diverse molecular mechanisms. In the Wnt/Frizzled pathway, inhibition of glycogen synthase kinase-3beta leads to an increased amount of beta-catenin, which can act as a transcription factor for several hypertrophy-associated target genes. In this study we subjected mice lacking the Dvl-1 gene and their wild-type littermates to thoracic aortic constriction for 7, 14, and 35 days. In mice lacking the Dvl-1 gene, 7 days of pressure overload-induced increases in left ventricular posterior wall thickness and expression of atrial natriuretic factor and brain natriuretic protein were attenuated compared with their wild-type littermates. Beta-catenin protein amount was reduced in the group lacking the Dvl-1 gene, and an increased glycogen synthase kinase-3beta activity was observed. Moreover, the increase in the amount of Ser(473)-phosphorylated Akt, a stimulator of cardiac hypertrophy, was lower in the group lacking the Dvl-1 gene. In conclusion, we have demonstrated that interruption of Wnt signaling in the mice lacking the Dvl-1 gene attenuates the onset of pressure overload-induced cardiac hypertrophy through mechanisms involving glycogen synthase kinase-3beta and Akt. Therefore, the Wnt/Frizzled pathway may provide novel therapeutic targets for antihypertrophic therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17210832     DOI: 10.1161/01.HYP.0000255946.55091.24

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  45 in total

Review 1.  A Land of Controversy: Fibroblast Growth Factor-23 and Uremic Cardiac Hypertrophy.

Authors:  Jing-Fu Bao; Pan-Pan Hu; Qin-Ying She; Aiqing Li
Journal:  J Am Soc Nephrol       Date:  2020-06-11       Impact factor: 10.121

Review 2.  Pathophysiology of Aortic Valve Stenosis: Is It Both Fibrocalcific and Sex Specific?

Authors:  Yoginee Sritharen; Maurice Enriquez-Sarano; Hartzell V Schaff; Grace Casaclang-Verzosa; Jordan D Miller
Journal:  Physiology (Bethesda)       Date:  2017-05

Review 3.  The Wnt signaling pathway: aging gracefully as a protectionist?

Authors:  Kenneth Maiese; Faqi Li; Zhao Zhong Chong; Yan Chen Shang
Journal:  Pharmacol Ther       Date:  2008-02-11       Impact factor: 12.310

4.  Gene expression profiling of HGF/Met activation in neonatal mouse heart.

Authors:  Stefano Gatti; Christian Leo; Simona Gallo; Valentina Sala; Enrico Bucci; Massimo Natale; Daniela Cantarella; Enzo Medico; Tiziana Crepaldi
Journal:  Transgenic Res       Date:  2012-12-06       Impact factor: 2.788

Review 5.  The importance of Wnt signaling in cardiovascular development.

Authors:  Ying Tian; Ethan David Cohen; Edward E Morrisey
Journal:  Pediatr Cardiol       Date:  2009-12-05       Impact factor: 1.655

Review 6.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis.

Authors:  P H Sugden; S J Fuller; S C Weiss; A Clerk
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 7.  A "FOXO" in sight: targeting Foxo proteins from conception to cancer.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Med Res Rev       Date:  2009-05       Impact factor: 12.944

Review 8.  Triple play: promoting neurovascular longevity with nicotinamide, WNT, and erythropoietin in diabetes mellitus.

Authors:  Kenneth Maiese
Journal:  Biomed Pharmacother       Date:  2008-02-20       Impact factor: 6.529

Review 9.  Therapeutic promise and principles: metabotropic glutamate receptors.

Authors:  Kenneth Maiese; Zhao Zhong Chong; Yan Chen Shang; Jinling Hou
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

10.  Active Wnt signaling in response to cardiac injury.

Authors:  Martinus I F J Oerlemans; Marie-José Goumans; Ben van Middelaar; Hans Clevers; Pieter A Doevendans; Joost P G Sluijter
Journal:  Basic Res Cardiol       Date:  2010-04-07       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.